Hubei Biocause Pharmaceutical (000627.SZ): CHINA BEST Life Insurance's cumulative original insurance premium income in 2024 is about 34.639 billion yuan.

10/01/2025

GMT Eight

Hubei Biocause Pharmaceutical (000627.SZ) announced that its controlling subsidiary CHINA BEST Life Insurance Co., Ltd. had accumulated gross insurance premiums of approximately 34.639 billion RMB from January 1, 2024 to December 31, 2024.

TRANSCENTA-B (06628) repurchased 10,000 shares on January 10th.

Weichai Power(02338): Li Pengcheng resigns as CEO.

Contact: contact@gmteight.com

Hubei Biocause Pharmaceutical (000627.SZ): CHINA BEST Life Insurance's cumulative original insurance premium income in 2024 is about 34.639 billion yuan.

RECOMMEND

SHIMAO GROUP (00813) is being filed for liquidation by Deeply Connected Holdings Ltd.

IMOTIONAUTOTECH (01274): China Securities Regulatory Commission issued a filing notice about the full circulation of the company's H shares.

US Stock Market Move | Nasdaq Golden Dragon China Index fell more than 3% in early trading, with popular Chinese concept stocks falling across the board.